Literature DB >> 178682

Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.

I Valverde, H M Lemon, A Kessinger, R H Unger.   

Abstract

Gel filtration of plasma from a patient with a clinical syndrome of glucagonoma and a total plasma glucagon level of 2600 pg/ml, revealed the four glucagon immunoreactive fractions found in normal subjects. The total hyperglucagonemia observed was due to high levels of true glucagon and proglucagon moieties. The so-called "big plasma glucagon" (BPG) measured 190 pg/ml (normal average 113 +/- 79 pg/ml, Mean +/- SD, N = 10); the large glucagon immunoreactivity, LGI (9000 mol wt), measured 625 pg/ml (normal average 11 +/- 16 pg/ml); the true glucagon accounted for 1435 pg/ml (normal average 31 +/- 29 pg/ml); and the small glucagon immunoreactive fraction (approximately 2000 mol wt) measured 35 pg/ml (normal average 26 +/- 18 pg/ml). The high levels of LGI, considered a candidate for proglucagon, may reflect the increased secretory activity of the tumor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 178682     DOI: 10.1210/jcem-42-5-804

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Secretion by glucagonomas of a possible glucagon precursor.

Authors:  G C Weir; E S Horton; T T Aoki; D Slovik; J Jaspan; A H Rubenstein
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

2.  Dominant inheritance of large molecular weight immunoreactive glucagon.

Authors:  J P Palmer; P L Werner; J W Benson; J W Ensinck
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

3.  The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.

Authors:  F Jockenhövel; S Lederbogen; T Olbricht; H Schmidt-Gayk; E P Krenning; S W Lamberts; D Reinwein
Journal:  Clin Investig       Date:  1994-01

4.  Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.

Authors:  S Del Prato; A Rovira; P Tessari; A Avogaro; R Nosadini; I Valverde; R Trevisan; A Tiengo
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 5.  Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

Authors:  E Ruttman; G Klöppel; G Bommer; M Kiehn; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

6.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.